Onyx Pharmaceuticals, Inc. today announced that it will delay its New Drug Application filing for carfilzomib based on a recent meeting with the Chemistry, Manufacturing and Controls review division of the US Food and Drug Administration.
Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib